It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...

United Community Banks, Inc. (NASDAQ:UCB – Get Free Report)’s stock price reached a new 52-week high during trading on Friday . The stock traded as high as $33.62 and last traded at $33.49, with a ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Commemorating a night full of soulful music, incredible theatricals, mouthwatering food and inspirational dialogues, UCB ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus ...

Korea on Friday approved UCB Korea's new drug for the treatment of a chronic muscle-weakening disease called generalized ...

UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free ...

The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...

The board of United Community Banks, Inc. ( NYSE:UCB ) has announced that it will pay a dividend of $0.24 per share ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...